Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Table of Contents

Table of Contents CLINICAL PHARMACOLOGY and ~I ERA PE UTI C S volume 12 number 2 part 2 March-April, 1971 Copyright © 1971 by The C. V. Mosby Company 317 Introduction Fletcher McDowell, M.D., New York, N. Y. 319 Parkinsonism and levodopa George C. Cotzias, M.D., Paul S. Papavasiliou, M.D., Andreas Steck, M.D., and Simone Duby, M.D., Upton, N. Y., Brookhaven National Laboratory Associated Universities, Inc. 323 Status of the clinical evaluation of levodopa in the treatment of Parkinson's disease and syndrome Ilarrison M. Langrall, M.D., and Clifford Joseph, M.D., Nutley, N. ]., Hoffmann-La Roche Inc. continued on page 4 March-April, 1971 Part 2 page 3 Table of contents continued 332 Levodopa and parkinsonism: Clinical impressions Melvin D. Yahr, M.D., New York, N. Y., Parkinson Research Center, Columbia University College of Physicians & Surgeons 335 Clinical laboratory abnormalities Fletcher McDowell, M.D., New York, N. Y., Department of Neurology, Cornell University Medical Center 340 The choreoathetoid movement disorder induced by levodopa Charles H. Markham, M.D., Los Angeles, Calif., Department of Neurology, University of California Los Angeles School of Medicine 344 Selective rise in brain dopamine by inhibition of extracerebral levodopa decarboxylation Alfred Pletscher, M.D., and Giuseppe Bartholini, M.D., Basel, Switzer­ land, Research Department, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical Pharmacology & Therapeutics Wiley

Table of Contents

Clinical Pharmacology & Therapeutics , Volume 12 (2part2) – Mar 1, 1971
Download PDF
3 pages

Loading next page...
 
/lp/wiley/table-of-contents-oIOmAFU8vp

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wiley
Copyright
© American Society for Clinical Pharmacology and Therapeutic
ISSN
0009-9236
eISSN
1532-6535
DOI
10.1002/cpt1971122part2toc
Publisher site
See Article on Publisher Site

Abstract

CLINICAL PHARMACOLOGY and ~I ERA PE UTI C S volume 12 number 2 part 2 March-April, 1971 Copyright © 1971 by The C. V. Mosby Company 317 Introduction Fletcher McDowell, M.D., New York, N. Y. 319 Parkinsonism and levodopa George C. Cotzias, M.D., Paul S. Papavasiliou, M.D., Andreas Steck, M.D., and Simone Duby, M.D., Upton, N. Y., Brookhaven National Laboratory Associated Universities, Inc. 323 Status of the clinical evaluation of levodopa in the treatment of Parkinson's disease and syndrome Ilarrison M. Langrall, M.D., and Clifford Joseph, M.D., Nutley, N. ]., Hoffmann-La Roche Inc. continued on page 4 March-April, 1971 Part 2 page 3 Table of contents continued 332 Levodopa and parkinsonism: Clinical impressions Melvin D. Yahr, M.D., New York, N. Y., Parkinson Research Center, Columbia University College of Physicians & Surgeons 335 Clinical laboratory abnormalities Fletcher McDowell, M.D., New York, N. Y., Department of Neurology, Cornell University Medical Center 340 The choreoathetoid movement disorder induced by levodopa Charles H. Markham, M.D., Los Angeles, Calif., Department of Neurology, University of California Los Angeles School of Medicine 344 Selective rise in brain dopamine by inhibition of extracerebral levodopa decarboxylation Alfred Pletscher, M.D., and Giuseppe Bartholini, M.D., Basel, Switzer­ land, Research Department,

Journal

Clinical Pharmacology & Therapeutics – Wiley

Published: Mar 1, 1971

There are no references for this article.